P2X7 is a Cytotoxic Receptor….maybe Not: Implications for Cancer

Overview

Journal Purinergic Signal

Publisher Springer

Date 2020 Oct 4

PMID 33011962

Citations 8

Authors

Francesco Di Virgilio

Affiliations

Soon will be listed here.

Abstract

The tumor microenvironment is rich in extracellular ATP. This nucleotide affects both cancer and infiltrating immune cell responses by acting at P2 receptors, chiefly P2X7. ATP is then degraded to generate adenosine, a very powerful immunosuppressant. The purinergic hypothesis put forward by Geoff Burnstock prompted innovative investigation in this field and provided the intellectual framework to interpret a myriad of experimental findings. This is a short appraisal of how Geoff's inspiration influenced cancer studies and my own investigation highlighting the key role of the P2X7 receptor.

Citing Articles

P2X Receptor and Extracellular Vesicle Release.

Golia M, Gabrielli M, Verderio C Int J Mol Sci. 2023; 24(12).

PMID: 37372953 PMC: 10298639. DOI: 10.3390/ijms24129805.

Microglia and Neuroinflammation: Crucial Pathological Mechanisms in Traumatic Brain Injury-Induced Neurodegeneration.

Shao F, Wang X, Wu H, Wu Q, Zhang J Front Aging Neurosci. 2022; 14:825086.

PMID: 35401152 PMC: 8990307. DOI: 10.3389/fnagi.2022.825086.

Extracellular HSP90 Machineries Build Tumor Microenvironment and Boost Cancer Progression.

Poggio P, Sorge M, Secli L, Brancaccio M Front Cell Dev Biol. 2021; 9:735529.

PMID: 34722515 PMC: 8551675. DOI: 10.3389/fcell.2021.735529.

P2X Receptors in Neurodegeneration: Potential Therapeutic Applications From Basic to Clinical Approaches.

Territo P, Zarrinmayeh H Front Cell Neurosci. 2021; 15:617036.

PMID: 33889073 PMC: 8055960. DOI: 10.3389/fncel.2021.617036.

P2X7: a receptor with a split personality that raises new hopes for anti-cancer therapy.

Sarti A, Vultaggio-Poma V, Di Virgilio F Purinergic Signal. 2021; 17(2):175-178.

PMID: 33818742 PMC: 8155152. DOI: 10.1007/s11302-021-09783-w.

References

Di Virgilio F, Adinolfi E . Extracellular purines, purinergic receptors and tumor growth. Oncogene. 2016; 36(3):293-303. PMC: 5269532. DOI: 10.1038/onc.2016.206. View

Borges da Silva H, Beura L, Wang H, Hanse E, Gore R, Scott M . The purinergic receptor P2RX7 directs metabolic fitness of long-lived memory CD8 T cells. Nature. 2018; 559(7713):264-268. PMC: 6054485. DOI: 10.1038/s41586-018-0282-0. View

Adinolfi E, Callegari M, Ferrari D, Bolognesi C, Minelli M, Wieckowski M . Basal activation of the P2X7 ATP receptor elevates mitochondrial calcium and potential, increases cellular ATP levels, and promotes serum-independent growth. Mol Biol Cell. 2005; 16(7):3260-72. PMC: 1165409. DOI: 10.1091/mbc.e04-11-1025. View

Rapaport E . Experimental cancer therapy in mice by adenine nucleotides. Eur J Cancer Clin Oncol. 1988; 24(9):1491-7. DOI: 10.1016/0277-5379(88)90340-9. View

Steinberg T, Silverstein S . Extracellular ATP4- promotes cation fluxes in the J774 mouse macrophage cell line. J Biol Chem. 1987; 262(7):3118-22. View

Ghiringhelli F, Apetoh L, Tesniere A, Aymeric L, Ma Y, Ortiz C . Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med. 2009; 15(10):1170-8. DOI: 10.1038/nm.2028. View

Gordon J . Extracellular ATP: effects, sources and fate. Biochem J. 1986; 233(2):309-19. PMC: 1153029. DOI: 10.1042/bj2330309. View

Di Virgilio F, Giuliani A, Vultaggio-Poma V, Falzoni S, Sarti A . Non-nucleotide Agonists Triggering P2X7 Receptor Activation and Pore Formation. Front Pharmacol. 2018; 9:39. PMC: 5799242. DOI: 10.3389/fphar.2018.00039. View

Adinolfi E, Raffaghello L, Giuliani A, Cavazzini L, Capece M, Chiozzi P . Expression of P2X7 receptor increases in vivo tumor growth. Cancer Res. 2012; 72(12):2957-69. DOI: 10.1158/0008-5472.CAN-11-1947. View

10.

Jamieson G, Snook M, Thurlow P, Wiley J . Extracellular ATP causes of loss of L-selectin from human lymphocytes via occupancy of P2Z purinocepters. J Cell Physiol. 1996; 166(3):637-42. DOI: 10.1002/(SICI)1097-4652(199603)166:3<637::AID-JCP19>3.0.CO;2-3. View

11.

Burnstock G, Knight G . The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression. Purinergic Signal. 2017; 14(1):1-18. PMC: 5842154. DOI: 10.1007/s11302-017-9593-0. View

12.

Elssner A, Duncan M, Gavrilin M, Wewers M . A novel P2X7 receptor activator, the human cathelicidin-derived peptide LL37, induces IL-1 beta processing and release. J Immunol. 2004; 172(8):4987-94. DOI: 10.4049/jimmunol.172.8.4987. View

13.

Shabbir M, Thompson C, Jarmulowiczc M, Mikhailidis D, Burnstock G . Effect of extracellular ATP on the growth of hormone-refractory prostate cancer in vivo. BJU Int. 2008; 102(1):108-12. DOI: 10.1111/j.1464-410X.2008.07578.x. View

14.

Gilbert S, Gidley Baird A, Glazer S, Barden J, Glazer A, Teh L . A phase I clinical trial demonstrates that nfP2X -targeted antibodies provide a novel, safe and tolerable topical therapy for basal cell carcinoma. Br J Dermatol. 2017; 177(1):117-124. DOI: 10.1111/bjd.15364. View

15.

Wiley J, Chen R, Jamieson G . The ATP4- receptor-operated channel (P2Z class) of human lymphocytes allows Ba2+ and ethidium+ uptake: inhibition of fluxes by suramin. Arch Biochem Biophys. 1993; 305(1):54-60. DOI: 10.1006/abbi.1993.1392. View

16.

Di Virgilio F . Purines, purinergic receptors, and cancer. Cancer Res. 2012; 72(21):5441-7. DOI: 10.1158/0008-5472.CAN-12-1600. View

17.

Burnstock G, Di Virgilio F . Purinergic signalling and cancer. Purinergic Signal. 2013; 9(4):491-540. PMC: 3889385. DOI: 10.1007/s11302-013-9372-5. View

18.

Adinolfi E, Capece M, Franceschini A, Falzoni S, Giuliani A, Rotondo A . Accelerated tumor progression in mice lacking the ATP receptor P2X7. Cancer Res. 2014; 75(4):635-44. DOI: 10.1158/0008-5472.CAN-14-1259. View

19.

Di Virgilio F, Schmalzing G, Markwardt F . The Elusive P2X7 Macropore. Trends Cell Biol. 2018; 28(5):392-404. DOI: 10.1016/j.tcb.2018.01.005. View

20.

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View